A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF INTRAVENOUS BRIVARACETAM IN SUBJECTS ¿1 MONTH TO <16 YEARS OF AGE WITH EPILEPSY PHASE 2

Administered By

Awarded By

Contributors

Start/End

  • July 3, 2018 - November 30, 2021